CE Mark for New Mitral Valve Repair Technology
Published date : 07 January 2013
Article date : 07 January 2013
The Wall Street Journal reports that NeoChord has announced that it has received a CE mark for its DS1000 System that allows the implantation of artificial chordae tendinae for the repair of mitral valve prolapse via a transapical off-pump procedure.
The manufacturer has also started the 50 patient Transapical Artificial Chordae Tendinae Registry, with first commercial European procedures scheduled for the first quarter of 2013.
They are described as "meaningful steps forward in the treatment of patients with severe mitral regurgitation," said Dr. Giovanni Speziali, the primary inventor of NeoChord's technology. He goes on to say that "The NeoChord procedure allows patients an alternative to still undergo a quality repair without enduring the rigors of traditional treatment via open-chest surgery performed on a stopped heart."
NeoChord is a privately held medical technology company focused on advancing the treatment of mitral regurgitation.
The NeoChord device is not available for commercial use in the US.
Source: Wall Street Journal, 4th January 2013.
